Skip to content

Study · Randomized controlled trial · 2010

10 results

Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer.

Smith MR, Klotz L, Persson BE, Olesen TK, Wilde AA

The Journal of urology16 Oct 2010Cited by 57 (Europe PMC)

PMID20952020 (opens in a new tab)PMCIDPMC3047399 (opens in a new tab)DOI10.1016/j.juro.2010.08.012 (opens in a new tab)PepBankPUB-20952020
Source linkPubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In prostate cancer patients, mean QTcF change did not differ significantly between degarelix and leuprolide.

    In plain wordsIn prostate cancer patients, mean QTcF change did not differ significantly between degarelix and leuprolide.

    Peptide
    Degarelix
    Outcome
    No significant changeMean QTcF change
    Study

    n: not reported in source

    Comparator
    leuprolide
    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Source sentences

    Summary
    There were no significant differences between treatment groups for mean change in Fridericia's correction of QT during the trial.
    1 context sentence
    Summary · context
    This is the first report to our knowledge on cardiovascular safety data from a completed 1-year randomized controlled trial of leuprolide acetate vs degarelix.
  2. 02HumanRandomized controlled trialSafety outcome

    In prostate cancer patients, mean QTcF change did not differ significantly between leuprolide and degarelix.

    In plain wordsIn prostate cancer patients, mean QTcF change did not differ significantly between leuprolide and degarelix.

    Peptide
    Leuprolide
    Outcome
    No significant changeMean QTcF change
    Study

    n: not reported in source

    Comparator
    degarelix
    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Source sentences

    Summary
    There were no significant differences between treatment groups for mean change in Fridericia's correction of QT during the trial.
    1 context sentence
    Summary · context
    This is the first report to our knowledge on cardiovascular safety data from a completed 1-year randomized controlled trial of leuprolide acetate vs degarelix.
  3. 03HumanRandomized controlled trialSafety outcome

    In prostate cancer patients, QTcF of at least 500 milliseconds occurred in 2 degarelix recipients, less than 1%, versus 2 leuprolide recipients, 1%.

    In plain wordsIn prostate cancer patients, markedly abnormal QTcF occurred in 2 degarelix recipients versus 2 leuprolide recipients.

    Peptide
    Degarelix
    Outcome
    Direction not reportedQTcF at least 500 milliseconds
    Study

    n: not reported in source

    Comparator
    leuprolide
    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Measurements

    Subjects with QTcF >=500 ms
    2 subjects
    pooled degarelix group
    Subjects with QTcF >=500 ms
    < 1%
    pooled degarelix group
    Subjects with QTcF >=500 ms
    2 subjects
    leuprolide group
    Subjects with QTcF >=500 ms
    1%
    leuprolide group

    Source sentences

    Summary
    Markedly abnormal Fridericia's correction of QT values (500 milliseconds or greater) were observed in only a small number of subjects by treatment group, that is 2 (less than 1%) in the pooled degarelix group and 2 (1%) in the leuprolide group.
    1 context sentence
    Summary · context
    This is the first report to our knowledge on cardiovascular safety data from a completed 1-year randomized controlled trial of leuprolide acetate vs degarelix.
  4. 04HumanRandomized controlled trialSafety outcome

    In prostate cancer patients, QTcF of at least 500 milliseconds occurred in 2 leuprolide recipients, 1%, versus 2 degarelix recipients, less than 1%.

    In plain wordsIn prostate cancer patients, markedly abnormal QTcF occurred in 2 leuprolide recipients versus 2 degarelix recipients.

    Peptide
    Leuprolide
    Outcome
    Direction not reportedQTcF at least 500 milliseconds
    Study

    n: not reported in source

    Comparator
    degarelix
    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Measurements

    Subjects with QTcF >=500 ms
    2 subjects
    leuprolide group
    Subjects with QTcF >=500 ms
    1%
    leuprolide group
    Subjects with QTcF >=500 ms
    2 subjects
    pooled degarelix group
    Subjects with QTcF >=500 ms
    < 1%
    pooled degarelix group

    Source sentences

    Summary
    Markedly abnormal Fridericia's correction of QT values (500 milliseconds or greater) were observed in only a small number of subjects by treatment group, that is 2 (less than 1%) in the pooled degarelix group and 2 (1%) in the leuprolide group.
    1 context sentence
    Summary · context
    This is the first report to our knowledge on cardiovascular safety data from a completed 1-year randomized controlled trial of leuprolide acetate vs degarelix.
  5. 05HumanRandomized controlled trialSafety outcome

    In prostate cancer patients, supraventricular arrhythmias affected 2% with degarelix versus 4% with leuprolide.

    In plain wordsIn prostate cancer patients, supraventricular arrhythmias affected 2% with degarelix versus 4% with leuprolide.

    Peptide
    Degarelix
    Outcome
    DecreaseSupraventricular arrhythmias
    Study

    n: not reported in source

    Comparator
    leuprolide
    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Measurements

    Supraventricular arrhythmias
    2%
    pooled degarelix group
    Supraventricular arrhythmias
    4%
    leuprolide group

    Source sentences

    Summary
    Supraventricular arrhythmias were the most common type of arrhythmias, affecting 2% of subjects in the pooled degarelix group and 4% in the leuprolide group.
    1 context sentence
    Summary · context
    This is the first report to our knowledge on cardiovascular safety data from a completed 1-year randomized controlled trial of leuprolide acetate vs degarelix.
  6. 06HumanRandomized controlled trialSafety outcome

    In prostate cancer patients, supraventricular arrhythmias affected 4% with leuprolide versus 2% with degarelix.

    In plain wordsIn prostate cancer patients, supraventricular arrhythmias affected 4% with leuprolide versus 2% with degarelix.

    Peptide
    Leuprolide
    Outcome
    IncreaseSupraventricular arrhythmias
    Study

    n: not reported in source

    Comparator
    degarelix
    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Measurements

    Supraventricular arrhythmias
    4%
    leuprolide group
    Supraventricular arrhythmias
    2%
    pooled degarelix group

    Source sentences

    Summary
    Supraventricular arrhythmias were the most common type of arrhythmias, affecting 2% of subjects in the pooled degarelix group and 4% in the leuprolide group.
    1 context sentence
    Summary · context
    This is the first report to our knowledge on cardiovascular safety data from a completed 1-year randomized controlled trial of leuprolide acetate vs degarelix.
  7. 07HumanRandomized controlled trialSafety outcome

    In prostate cancer patients, other arrhythmias occurred in 1% or less of each treatment group, including degarelix.

    In plain wordsIn prostate cancer patients, other arrhythmias occurred in 1% or less with either degarelix or leuprolide.

    Peptide
    Degarelix
    Outcome
    Direction not reportedOther arrhythmias
    Study

    n: not reported in source

    Comparator
    leuprolide
    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Measurements

    Other arrhythmias
    ≤ 1%
    each treatment group, including degarelix

    Source sentences

    Summary
    Other arrhythmias occurred in 1% or less of subjects by treatment group.
    1 context sentence
    Summary · context
    This is the first report to our knowledge on cardiovascular safety data from a completed 1-year randomized controlled trial of leuprolide acetate vs degarelix.
  8. 08HumanRandomized controlled trialSafety outcome

    In prostate cancer patients, other arrhythmias occurred in 1% or less of each treatment group, including leuprolide.

    In plain wordsIn prostate cancer patients, other arrhythmias occurred in 1% or less with either leuprolide or degarelix.

    Peptide
    Leuprolide
    Outcome
    Direction not reportedOther arrhythmias
    Study

    n: not reported in source

    Comparator
    degarelix
    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Measurements

    Other arrhythmias
    ≤ 1%
    each treatment group, including leuprolide

    Source sentences

    Summary
    Other arrhythmias occurred in 1% or less of subjects by treatment group.
    1 context sentence
    Summary · context
    This is the first report to our knowledge on cardiovascular safety data from a completed 1-year randomized controlled trial of leuprolide acetate vs degarelix.
  9. 09HumanRandomized controlled trialSafety outcome

    In prostate cancer patients, ischemic heart disease occurred in 4% with degarelix versus 10% with leuprolide.

    In plain wordsIn prostate cancer patients, ischemic heart disease occurred in 4% with degarelix versus 10% with leuprolide.

    Peptide
    Degarelix
    Outcome
    DecreaseIschemic heart disease
    Study

    n: not reported in source

    Comparator
    leuprolide
    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Measurements

    Ischemic heart disease
    4%
    degarelix-treated subjects
    Ischemic heart disease
    10%
    leuprolide-treated subjects

    Source sentences

    Summary
    The most frequently reported cardiac disorder was ischemic heart disease, which occurred in 4% of subjects treated with degarelix and 10% of those on leuprolide.
    1 context sentence
    Summary · context
    This is the first report to our knowledge on cardiovascular safety data from a completed 1-year randomized controlled trial of leuprolide acetate vs degarelix.
  10. 10HumanRandomized controlled trialSafety outcome

    In prostate cancer patients, ischemic heart disease occurred in 10% with leuprolide versus 4% with degarelix.

    In plain wordsIn prostate cancer patients, ischemic heart disease occurred in 10% with leuprolide versus 4% with degarelix.

    Peptide
    Leuprolide
    Outcome
    IncreaseIschemic heart disease
    Study

    n: not reported in source

    Comparator
    degarelix
    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Measurements

    Ischemic heart disease
    10%
    leuprolide-treated subjects
    Ischemic heart disease
    4%
    degarelix-treated subjects

    Source sentences

    Summary
    The most frequently reported cardiac disorder was ischemic heart disease, which occurred in 4% of subjects treated with degarelix and 10% of those on leuprolide.
    1 context sentence
    Summary · context
    This is the first report to our knowledge on cardiovascular safety data from a completed 1-year randomized controlled trial of leuprolide acetate vs degarelix.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 2

    27 Oct 2026, 16:37 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.